Bibliografisk träff 2024-06-11 Exploring the structural activity relationship of the Osimertinib: A covalent inhibitor of double mutant EGFR<sup>L858R/T790M</sup> tyrosine kinase for the treatment of Non-Small Cell Lung Cancer (NSCLC). Patil BR, Bhadane KV, Ahmad I, Agrawal YJ, Shimpi AA, Dhangar MS, Patel HM. Bioorg Med Chem · review; journal article · DOI 10.1016/j.bmc.2024.117796
Bibliografisk träff 2021-02-25 Structural modifications on indole and pyrimidine rings of osimertinib lead to high selectivity towards L858R/T790M double mutant enzyme and potent antitumor activity. Liu Q, Luo Y, Li Z, Chen C, Fang L. Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2021.116094